Adjuvant chemoradiotherapy led to improved overall survival (OS) and recurrence-free survival (RFS) vs radiotherapy alone in patients with high-risk endometrial cancer, according to 10-year data from the phase 3 PORTEC-3 trial (NCT00411138)…
Adjuvant Chemoradiotherapy Provides Long-Term Survival Benefits in High-Risk Endometrial Cancer
